CelLBxHealth develops and provides liquid biopsy technology and laboratory services for circulating tumor cell (CTC) detection and analysis in cancer care. The company offers the FDA-cleared Parsortix platform for isolating intact CTCs from blood, along with specialized laboratory testing services for biomarker assessment and therapy selection across multiple cancer types.